Adam Havey Net Worth

The estimated Net Worth of Adam Havey is at least $7.61 Миллион dollars as of 1 March 2021. Mr. Havey owns over 37,279 units of Emergent Biosolutions Inc stock worth over $441,596 and over the last 14 years he sold EBS stock worth over $5,323,235. In addition, he makes $1,845,370 as Executive Vice President - Business Operations at Emergent Biosolutions Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr. Havey EBS stock SEC Form 4 insiders trading

Adam has made over 24 trades of the Emergent Biosolutions Inc stock since 2011, according to the Form 4 filled with the SEC. Most recently he exercised 37,279 units of EBS stock worth $1,524,711 on 1 March 2021.

The largest trade he's ever made was exercising 37,423 units of Emergent Biosolutions Inc stock on 17 April 2020 worth over $1,064,684. On average, Adam trades about 5,421 units every 73 days since 2011. As of 1 March 2021 he still owns at least 58,335 units of Emergent Biosolutions Inc stock.

You can see the complete history of Mr. Havey stock trades at the bottom of the page.

Adam Havey biography

Adam Havey is Executive Vice President - Business Operations of the Company since April 2017. He previously served as executive vice president and president, biodefense division from March 2011 to March 2017. Prior to that, Mr. Havey held various roles, including president of Emergent Biodefense Operations Lansing LLC from January 2009 to February 2011, vice president of business operations from November 2007 to December 2008, and senior director of manufacturing development from June 2006 to November 2007. Prior to joining us, Mr. Havey served in product development for Eli Lilly. He received a B.S. degree in chemical engineering from Michigan State University.

What is the salary of Adam Havey?

As the Executive Vice President - Business Operations of Emergent Biosolutions Inc, the total compensation of Adam Havey at Emergent Biosolutions Inc is $1,845,370. There are 5 executives at Emergent Biosolutions Inc getting paid more, with Robert Kramer having the highest compensation of $3,693,820.

How old is Adam Havey?

Adam Havey is 49, he's been the Executive Vice President - Business Operations of Emergent Biosolutions Inc since 2017. There are 18 older and 3 younger executives at Emergent Biosolutions Inc. The oldest executive at Emergent Biosolutions Inc is Louis Sullivan, 86, who is the Independent Director.

What's Adam Havey's mailing address?

Adam's mailing address filed with the SEC is 400 PROFESSIONAL DR, SUITE 400, , GAITHERSBURG, MD, 20879.

Insiders trading at Emergent Biosolutions Inc

Over the last 18 years, insiders at Emergent Biosolutions Inc have traded over $131,382,266 worth of Emergent Biosolutions Inc stock and bought 4,647 units worth $138,981 . The most active insiders traders include Seamus Mulligan, Fuad El Hibri и Shahzad Malik. On average, Emergent Biosolutions Inc executives and independent directors trade stock every 21 days with the average trade being worth of $147,206. The most recent stock trade was executed by Kathryn C Zoon on 4 June 2024, trading 10,000 units of EBS stock currently worth $61,100.

What does Emergent Biosolutions Inc do?

emergent biosolutions is a global life sciences company dedicated to one simple mission—to protect and enhance life. we develop, manufacture, and deliver a portfolio of medical countermeasures for biological and chemical threats as well as emerging infectious diseases. through our work, we envision protecting and enhancing 50 million lives with our products by 2025. additional information about the company may be found at www.emergentbiosolutions.com. follow us @emergentbiosolu and @life_at_emergent

Complete history of Mr. Havey stock trades at Emergent Biosolutions Inc

Emergent Biosolutions Inc executives and stock owners

Emergent Biosolutions Inc executives and other stock owners filed with the SEC include:

• Robert Kramer,
  President, Chief Executive Officer, Director
• Fuad El-Hibri,
  Executive Chairman of the Board
• Robert G. Kramer,
  CEO, Pres & Exec. Director
• Richard Lindahl,
  Chief Financial Officer, Executive Vice President, Treasurer
• Atul Saran,
  Executive Vice President, Corporate Development, General Counsel and Corporate Secretary
• Adam Havey,
  Executive Vice President - Business Operations
• Fuad El-Hibri,
  Founder & Exec. Chairman
• Richard S. Lindahl,
  Exec. VP, CFO & Treasurer
• Adam R. Havey,
  Exec. VP & COO
• Atul Saran,
  Exec. VP of Corp. Devel. & Ext. Affairs and Gen. Counsel
• Seamus Mulligan,
  Director
• Ronald Richard,
  Lead Independent Director
• Zsolt Harsanyi,
  Independent Director
• Louis Sullivan,
  Independent Director
• Jerome Hauer,
  Independent Director
• George Joulwan,
  Independent Director
• Kathryn Zoon,
  Independent Director
• Sue Bailey,
  Independent Director
• Marvin White,
  Director
• Robert Burrows,
  Vice President, Investor Relations
• Sean Kirk,
  Executive Vice President, Manufacturing and Technical Operations
• Katherine Strei,
  Executive Vice President, Human Resources and Communications, Chief Human Resources Officer
• Katherine Strei,
  Exec. VP of HR & Chief HR Officer
• Nina DeLorenzo,
  Sr. VP of Global Communications & Public Affairs
• Lynn Kieffer,
  VP of Corp. Communications
• Howard Anderson,
  Sr. VP & Chief Information Officer
• Karen L. Smith,
  EVP, Chief Medical Officer
• John Niederhuber,
  Director
• Daniel Abdun Nabi,
  SVP Corp Aff, GC & Secretary
• L.L.C. Bio Pharm,,
  10% owner
• Stephen Lockhart,
  SVP Product Development
• L.L.C. Intervac,,
  10% owner
• Steven Chatfield,
  President, EPD UK & CSO
• R Don Elsey,
  VP Finance, CFO & Treasurer
• Barry Labinger,
  EVP, Biosciences Div.
• Denise Esposito,
  SVP Legal Affairs & GC
• L.L.C. Biologika,,
  
• Biologic Products, Inc. Mic...,
  
• Kyle Keese,
  SVP Mktg & Comm.
• Joe M Allbaugh,
  Director
• Mauro Gibellini,
  SVP Corporate Dev.
• Investments Ltd Microscience,
  10% owner
• Shahzad Malik,
  Director
• Edward Arcuri,
  EVP & COO
• Thomas Zink,
  SVP & CMO
• Robert Calvin Myers,
  
• Joseph C Papa,
  President and CEO
• Jennifer Lynne Fox,
  EVP, Ext Aff, GC, Corp Sec
• Keith Katkin,
  Director
• Coleen Glessner,
  EVP, Quality & Ethics, and CPL
• Sujata Tyagi Dayal,
  Director
• Paul Anthony Williams,
  SVP, Products Business
• William Hartzel,
  SVP, Bioservices
• Neal Franklin Fowler,
  Director
• Donald W De Golyer,
  Director